Gwendal L. M.
- Country
- France
- Department
- Centre d’investigation clinique – CIC-P
Research Overview
- Long-term Safety, Tolerability, and Efficacy of Subcutaneous Efgartigimod PH20 in Chronic Inflammatory Demyelinating Polyneuropathy: An Open-label Extension Study
- Phase 2 Multicenter Open-Label Study on Efficacy, Safety, and Tolerability of Riliprubart in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Efficacy and Safety of Nipocalimab in Adults with Chronic Inflammatory Demyelinating Polyneuropathy: A Randomized, Double-Blind, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 103 of 231 partner sites.
Specializations
Neurodegenerative Disorders
This investigator specializes in the treatment of Amyotrophic Lateral Sclerosis (ALS), conducting research into innovative therapeutic approaches including biomarker analysis and combination therapies.
- Blood neurofilament light chain assessment
- Blood-brain barrier integrity markers
- Combination therapy approaches
The research focuses on evaluating novel compounds and their effects on ALS progression.
Inflammatory Neuropathies
Extensive work in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), investigating multiple therapeutic agents for various patient subpopulations.
- Standard of care optimization
- Refractory CIDP management
- Novel therapeutic approaches
The investigator explores long-term safety and efficacy of various treatments for CIDP patients.
Specialized Neurological Conditions
Research extends to Multifocal Motor Neuropathy (MMN) and related immune system disorders, with a focus on innovative biological therapies.
- Long-term treatment outcomes
- Immunological interventions
- Safety and tolerability studies
Investigation of novel therapeutic agents for rare neurological conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.